Related Experiment Video
Updated: Feb 28, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Exploring the Potential of Receptor Silencing in the Tumor Microenvironment by RNA Interference
Karina Mayumi Tani Bezerra de Melo1, Beatriz Mendonça Alves Bandeira1, Pedro Vinícius Silva Novis1
1Laboratory of Molecular Studies and Experimental Therapy-LEMTE, Department of Genetics, Federal University of Pernambuco, Avenida da Engenharia S/N, Recife 50740-600, Pernambuco, Brazil.
Abstract:
Cancer is a heterogeneous disease caused by genetic and epigenetic factors, leading to alterations in signaling pathways and regulatory processes. Overall, the more commonly employed conventional treatments present side effects and resistance. Due to the diverse cellular composition of the tumor microenvironment, inhibition of cell communication by RNA interference (RNAi) has emerged as a strategy to regulate the expression of receptors linked to carcinogenesis. This review examines RNAi-mediated receptor silencing as a strategy to modify the tumor microenvironment, primarily in tumor cells, enhancing its vulnerability to immune cell destruction and reducing resistance to conventional therapies. In the tumor microenvironment, the silencing of immune checkpoints like PD-1 and CTLA-4 has demonstrated the ability to restore T cell function and enhance the efficacy of adoptive cell therapies. Additionally, the targeting of G protein-coupled receptors, including CXCR4, CCR5, and A2aR, as well as growth factor receptors such as VEGFR and EGFR, and interleukin receptors, interferes with pathways that are critical for tumor promotion, resulting in diminished angiogenesis, metastasis, and immunosuppression. These strategies utilize advanced delivery systems, including nanoparticles and exosomes, and show that silencing multiple targets can produce more effective antitumor outcomes than single-target methods, underscoring the significant potential of RNA interference in cancer treatment.
Insights
RNA interference (RNAi) offers a novel cancer treatment by silencing receptors that promote tumor growth and resistance. This approach modifies the tumor microenvironment, enhancing immune cell activity and improving responses to conventional therapies.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Cancer is a complex disease driven by genetic/epigenetic changes, often leading to treatment resistance.
- Conventional cancer therapies have limitations including side effects and acquired resistance.
- The tumor microenvironment plays a crucial role in cancer progression and immune evasion.
Purpose of the Study:
- To review RNA interference (RNAi)-mediated receptor silencing as a strategy to overcome cancer treatment resistance.
- To explore how RNAi can modify the tumor microenvironment to enhance anti-tumor immunity.
- To assess the potential of targeting multiple receptors simultaneously for improved therapeutic outcomes.
Main Methods:
- Review of studies utilizing RNA interference (RNAi) for gene silencing in cancer.
- Analysis of RNAi targeting of immune checkpoints (PD-1, CTLA-4) to restore T cell function.
- Examination of RNAi targeting of various receptors (GPCRs, growth factor, interleukin receptors) involved in tumor promotion.
- Investigation of advanced delivery systems like nanoparticles and exosomes for RNAi therapy.
Main Results:
- Silencing immune checkpoints (PD-1, CTLA-4) can restore T cell function and enhance adoptive cell therapy efficacy.
- Targeting receptors like CXCR4, CCR5, A2aR, VEGFR, EGFR, and interleukin receptors inhibits tumor growth, angiogenesis, metastasis, and immunosuppression.
- Multi-target RNAi strategies demonstrate superior antitumor effects compared to single-target approaches.
- Advanced delivery systems facilitate effective RNAi delivery within the tumor microenvironment.
Conclusions:
- RNA interference (RNAi) is a promising therapeutic strategy for cancer treatment.
- Modulating the tumor microenvironment via RNAi enhances tumor vulnerability and reduces treatment resistance.
- Targeting multiple receptors with RNAi offers a potent approach to combat cancer progression and improve therapeutic efficacy.
Related Concept Videos
02:15Experimental RNAi
01:22MicroRNAs
01:22MicroRNAs
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:30Small interfering RNAs (siRNA)